Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESSO 45 | Artificial intelligence as a surgical companion in colorectal cancer care

Domenico D’Ugo, MD, Fondazione Policlinico Gemelli, Rome, Italy, discusses the potential of artificial intelligence (AI) applications in colorectal cancer surgery, highlighting the importance of surgeon involvement and control in the decision-making process. AI tools can enhance specific tasks, such as identifying critical structures and planes of division, but the goal is to develop a comprehensive companion system that assists throughout the patient pathway, from diagnosis to treatment selection, without replacing the surgeon’s expertise. This interview took place at the 2026 European Society of Surgical Oncology (ESSO) Annual Meeting in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

I think that AI applications in surgery are a little bit more safe and filled with promises compared to what is going on in this enormous market advanced for AI applications in medicine, where the ability of diagnosing is made faster by applications that you cannot control because they are based upon a black box of reasoning with any confidential, you know, ability of the machine to explain to you how they made their decision...

I think that AI applications in surgery are a little bit more safe and filled with promises compared to what is going on in this enormous market advanced for AI applications in medicine, where the ability of diagnosing is made faster by applications that you cannot control because they are based upon a black box of reasoning with any confidential, you know, ability of the machine to explain to you how they made their decision. In surgery, surgeons make the difference because in surgery we have to sense and understand what are, in a video-based surgical operation, what are the main points that should be ameliorated and made more precise. Then we have to select this and give to the machine learning algorithm what we want to understand in terms of wrong or correct. And then, as things go by, we will learn to work together in providing big data, and this big data will come back to us and act at the end like an AI visual companion while we are operating. So it’s totally different compared to other kinds of applications where you delegate to the machine a diagnosis that should remain in your hands. Surgery will remain in your hands, but with the help of a special assistant that knows much more than you know, because he’s been assisting thousands of other people. Right now, we have a lot, really a lot of, we call them AI tools. They are not, you know, integrated systems of AI. They are just tools that enhance some specific task. So we can see better the recurrent laryngeal nerve in the thorax. We can identify the dangerous points and maintain a critical view of safety during a cholecystectomy or a major operation inside the abdomen or the thorax. In some cases, all because surgeons have been giving their major worries to the machine, we can highlight a plane of division in order for the surgeon to dissect without making any specific damage to the surrounding tissue. But these are separate tools. We are aiming to get much more. We would like a companion that in surgical oncology will accompany the entire patient pathway from the beginning, so the diagnosis, to the organization of his multidisciplinary discussion. The selection of opportunities in order to choose the best treatment in an era where there are so many new parameters making the difference, like molecular subtype of the tumor or augmented risk for patients that we call fragile. Not anybody should receive the same thing. And this is the way, based on data, in which we can receive assistance from the same system that then will accompany us during the operation, like I said before. Well, what we are afraid of is a total delegation of our task to the machine. But fortunately, in Europe, level five of confidence is not allowed for clinical use. So we should not be scared about a day where the robot is doing the operation without our participation. But I think that we would be participating in this process, guiding not the market, but the patient needs in using algorithms that will support us in making better choices that sometimes are not just in those challenging cases where you don’t know exactly what to do, but also in ordinary cases because there are every day more parameters and more factors that sometimes would totally change your decision-making process in deciding what is the treatment plan for a patient. So I think this will remain and this will be our best achievement if we learn how to interact with the big companies that are producing these tools.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.